Literature DB >> 31691873

Repeated stereotactic radiosurgery (SRS) using a non-coplanar mono-isocenter (HyperArc™) technique versus upfront whole-brain radiotherapy (WBRT): a matched-pair analysis.

Luca Nicosia1, Vanessa Figlia2, Rosario Mazzola2, Giuseppe Napoli2, Niccolò Giaj-Levra2, Francesco Ricchetti2, Michele Rigo2, Gianluigi Lunardi3, Davide Tomasini2,4, Marco L Bonù2,4, Stefanie Corradini5, Ruggero Ruggieri2, Filippo Alongi2,4.   

Abstract

Stereotactic radiosurgery (SRS) is an effective treatment option for multiple brain metastases (BMs). Modern mono-isocentric techniques allow the delivery of multiple stereotactic courses, in the event of intracranial failure. Nevertheless, limited data on effectiveness and toxicity have been reported in comparison to WBRT. Aim of this retrospective matched-pair analysis was to compare patients affected by limited BMs treated with multiple SRS courses using a mono-isocentric, non-coplanar technique (HyperArc™, Varian Medical System) to upfront WBRT. One hundred and two patients accounting for 677 BMs were treated with HyperArc™. In case of further intracranial progression, 44 treatment courses of 201 metastases in 19 patients, were treated by subsequent HyperArc™ courses. This population was matched with 38 patients treated with WBRT. The median BMs number was 4 (range 2-10) for HyperArc™ and 5 (range 2-10) for WBRT. Overall survival (OS) and toxicity were evaluated. The median follow-up was 9 months (range 3-40 months). The median OS was not reached (range 5-22 months) for HyperArc™ patients and 8 months (range 3-40 months) for WBRT patients, while the 1-year OS was 77% and 34.6% for HyperArc™ and WBRT, respectively (p = 0.001; HR 4.77, 95% CI 1.62-14.00). There was one case of radionecrosis. HyperArc™ is an effective and safe technique for the treatment of multiple BMs. In selected cases of intracranial oligorecurrence, further subsequent courses can be safely delivered with the same technical approach. Moreover, in patients with a limited number of BMs, SRS showed an improved survival outcome when compared to WBRT.

Entities:  

Keywords:  Brain metastases; HyperArc; Linac-based VMAT; Radiosurgery; Radiotherapy; Whole-brain radiotherapy

Mesh:

Year:  2019        PMID: 31691873     DOI: 10.1007/s10585-019-10004-3

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  40 in total

1.  Single-Isocenter Frameless Volumetric Modulated Arc Radiosurgery for Multiple Intracranial Metastases.

Authors:  Steven K M Lau; Kaveh Zakeri; Xiao Zhao; Ruben Carmona; Erik Knipprath; Daniel R Simpson; Sameer K Nath; Gwe-Ya Kim; Parag Sanghvi; Jona A Hattangadi-Gluth; Clark C Chen; Kevin T Murphy
Journal:  Neurosurgery       Date:  2015-08       Impact factor: 4.654

2.  Clinical Outcomes of Upfront Stereotactic Radiosurgery Alone for Patients With 5 to 15 Brain Metastases.

Authors:  Ryan T Hughes; Emory R McTyre; Michael LeCompte; Christina K Cramer; Michael T Munley; Adrian W Laxton; Stephen B Tatter; Jimmy Ruiz; Boris Pasche; Kounosuke Watabe; Michael D Chan
Journal:  Neurosurgery       Date:  2019-08-01       Impact factor: 4.654

3.  Linac-based radiosurgery for multiple brain metastases: Comparison between two mono-isocenter techniques with multiple non-coplanar arcs.

Authors:  Ruggero Ruggieri; Stefania Naccarato; Rosario Mazzola; Francesco Ricchetti; Stefanie Corradini; Alba Fiorentino; Filippo Alongi
Journal:  Radiother Oncol       Date:  2018-12-21       Impact factor: 6.280

4.  Patients with Long-Term Control of Systemic Disease Are a Favorable Prognostic Group for Treatment of Brain Metastases with Stereotactic Radiosurgery Alone.

Authors:  Daniel K Ebner; Daniel Gorovets; Paul Rava; Deus Cielo; Timothy J Kinsella; Thomas A DiPetrillo; Jaroslaw T Hepel
Journal:  World Neurosurg       Date:  2016-11-09       Impact factor: 2.104

5.  Radiosurgery for brain metastases: a score index for predicting prognosis.

Authors:  E Weltman; J V Salvajoli; R A Brandt; R de Morais Hanriot; F E Prisco; J C Cruz; S R de Oliveira Borges; D B Wajsbrot
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-03-15       Impact factor: 7.038

6.  Repeat Courses of Stereotactic Radiosurgery (SRS), Deferring Whole-Brain Irradiation, for New Brain Metastases After Initial SRS.

Authors:  David B Shultz; Leslie A Modlin; Priya Jayachandran; Rie Von Eyben; Iris C Gibbs; Clara Y H Choi; Steven D Chang; Griffith R Harsh; Gordon Li; John R Adler; Steven L Hancock; Scott G Soltys
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-28       Impact factor: 7.038

7.  Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO).

Authors:  Riccardo Soffietti; Ufuk Abacioglu; Brigitta Baumert; Stephanie E Combs; Sara Kinhult; Johan M Kros; Christine Marosi; Philippe Metellus; Alexander Radbruch; Salvador S Villa Freixa; Michael Brada; Carmine M Carapella; Matthias Preusser; Emilie Le Rhun; Roberta Rudà; Joerg C Tonn; Damien C Weber; Michael Weller
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

8.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

9.  Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases.

Authors:  Adam G Johnson; Jimmy Ruiz; Ryan Hughes; Brandi R Page; Scott Isom; John T Lucas; Emory R McTyre; Kristin W Houseknecht; Diandra N Ayala-Peacock; Daniel J Bourland; William H Hinson; Adrian W Laxton; Stephen B Tatter; Waldemar Debinski; Kounosuke Watabe; Michael D Chan
Journal:  Oncotarget       Date:  2015-08-07

10.  Second course of stereotactic radiosurgery for locally recurrent brain metastases: Safety and efficacy.

Authors:  Juliette Moreau; Toufic Khalil; Guillaume Dupic; Emmanuel Chautard; Jean-Jacques Lemaire; Florian Magnier; Véronique Dedieu; Michel Lapeyre; Pierre Verrelle; Julian Biau
Journal:  PLoS One       Date:  2018-04-05       Impact factor: 3.240

View more
  13 in total

1.  Reply to: The course of lung oligometastatic colorectal cancer may be a reflection of selection for treatment rather than an effect of stereotactic body radiotherapy.

Authors:  Luca Nicosia; Francesco Cuccia; Filippo Alongi
Journal:  Strahlenther Onkol       Date:  2020-11-26       Impact factor: 3.621

2.  Long-term disease outcome and volume-based decision strategy in a large cohort of multiple brain metastases treated with a mono-isocentric linac-based Stereotactic Radiosurgery technique.

Authors:  F Alongi; L Nicosia; V Figlia; N Giaj-Levra; F Cuccia; R Mazzola; F Ricchetti; M Rigo; C Vitale; A De Simone; S Naccarato; G Sicignano; D Gurrera; S Corradini; R Ruggeri
Journal:  Clin Transl Oncol       Date:  2021-02-11       Impact factor: 3.405

3.  Role of whole brain radiotherapy in the management of infratentorial metastases from lung and breast cancer.

Authors:  Bernardo Cacho-Díaz; Alejandra Alvarez-Alvarez; Karen Salmerón-Moreno; Oscar Rodríguez-Mayoral; Bernardino Gabriel Santiago-Concha; Oscar G Arrieta Rodríguez
Journal:  Rep Pract Oncol Radiother       Date:  2021-08-12

4.  Neuroinflammation After Stereotactic Radiosurgery-Induced Brain Tumor Disintegration Is Linked to Persistent Cognitive Decline in a Mouse Model of Metastatic Disease.

Authors:  Chengyan Chu; Catherine M Davis; Xiaoyan Lan; Robert D Hienz; Anna Jablonska; Aline M Thomas; Esteban Velarde; Shen Li; Miroslaw Janowski; Mihoko Kai; Piotr Walczak
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-05-26       Impact factor: 7.038

5.  Simultaneous stereotactic radiosurgery of multiple brain metastases using single-isocenter dynamic conformal arc therapy: a prospective monocentric registry trial.

Authors:  Raphael Bodensohn; Anna-Lena Kaempfel; Daniel Felix Fleischmann; Indrawati Hadi; Jan Hofmaier; Sylvia Garny; Michael Reiner; Robert Forbrig; Stefanie Corradini; Niklas Thon; Claus Belka; Maximilian Niyazi
Journal:  Strahlenther Onkol       Date:  2021-04-21       Impact factor: 3.621

6.  Repeated stereotactic radiosurgery for the treatment of relapsed brain metastases: is it time to give up whole-brain radiotherapy?

Authors:  Luca Nicosia; Vanessa Figlia; Niccolò Giaj-Levra; Giuseppe Minniti; Filippo Alongi
Journal:  Oncoscience       Date:  2020-04-24

7.  Reirradiation of Whole Brain for Recurrent Brain Metastases: A Case Report of Lung Cancer With 12-Year Survival.

Authors:  Minmin Li; Yanbo Song; Longhao Li; Jian Qin; Hongbin Deng; Tao Zhang
Journal:  Front Oncol       Date:  2021-11-26       Impact factor: 6.244

8.  Whole Brain Irradiation or Stereotactic RadioSurgery for five or more brain metastases (WHOBI-STER): A prospective comparative study of neurocognitive outcomes, level of autonomy in daily activities and quality of life.

Authors:  Gianluca Ferini; Anna Viola; Vito Valenti; Antonella Tripoli; Laura Molino; Valentina Anna Marchese; Salvatore Ivan Illari; Giuseppina Rita Borzì; Angela Prestifilippo; Giuseppe Emmanuele Umana; Emanuele Martorana; Gianluca Mortellaro; Giuseppe Ferrera; Alberto Cacciola; Sara Lillo; Antonio Pontoriero; Stefano Pergolizzi; Silvana Parisi
Journal:  Clin Transl Radiat Oncol       Date:  2021-12-02

9.  Immune checkpoint inhibition in patients treated with stereotactic radiation for brain metastases.

Authors:  Emily S Kowalski; Jill S Remick; Kai Sun; Gregory S Alexander; Rahul Khairnar; Emily Morse; Hua-Ren Cherng; Lars J Berg; Yannick Poirier; Narottam Lamichhane; Stewart Becker; Shifeng Chen; Jason K Molitoris; Young Kwok; William F Regine; Mark V Mishra
Journal:  Radiat Oncol       Date:  2020-10-27       Impact factor: 3.481

10.  Assessing efficacy and safety of stereotactic body radiation therapy for oligometastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) wild type.

Authors:  Xiaolong Hu; Hongqi Li; Hefei Liu; Zhifei Liu; Tingyi Xia; Jianchun Zhang; Yingjie Wang
Journal:  Transl Cancer Res       Date:  2021-01       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.